799,882 Shares in AxoGen, Inc. $AXGN Purchased by Next Century Growth Investors LLC

Posted by George Bondi on Jun 14th, 2026

Next Century Growth Investors LLC acquired a new position in AxoGen, Inc. (NASDAQ:AXGN – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 799,882 shares of the medical equipment provider’s stock, valued at approximately $26,180,000. AxoGen accounts for 1.8% of Next Century Growth Investors LLC’s portfolio, making the stock its 11th largest holding.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXGN. MCF Advisors LLC acquired a new stake in AxoGen in the fourth quarter worth about $30,000. Aquatic Capital Management LLC increased its position in AxoGen by 287.8% in the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 1,269 shares during the period. Arax Advisory Partners grew its position in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 819 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of AxoGen during the 4th quarter worth about $36,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of AxoGen during the 4th quarter worth about $39,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Erick Wayne Devinney sold 5,221 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $32.84, for a total transaction of $171,457.64. Following the sale, the insider owned 262,781 shares in the company, valued at $8,629,728.04. This represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Amy Mcbride Wendell sold 1,647 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the sale, the director owned 93,826 shares in the company, valued at approximately $3,996,987.60. This represents a 1.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 34,262 shares of company stock worth $1,440,250. 2.44% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AXGN. Citigroup restated an “outperform” rating on shares of AxoGen in a research report on Wednesday, April 29th. Raymond James Financial restated an “outperform” rating and set a $48.00 target price on shares of AxoGen in a research report on Wednesday, April 29th. HC Wainwright boosted their target price on AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered AxoGen from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Wells Fargo & Company boosted their target price on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, AxoGen currently has a consensus rating of “Moderate Buy” and an average price target of $46.50.

View Our Latest Stock Report on AxoGen

AxoGen Trading Up 1.5%

NASDAQ AXGN opened at $43.00 on Friday. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -67.19 and a beta of 1.12. AxoGen, Inc. has a 52 week low of $9.22 and a 52 week high of $45.83. The stock’s 50 day moving average price is $39.33 and its two-hundred day moving average price is $34.56. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10.

AxoGen (NASDAQ:AXGN – Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The company had revenue of $61.46 million for the quarter, compared to the consensus estimate of $57.85 million. As a group, analysts anticipate that AxoGen, Inc. will post -0.37 earnings per share for the current fiscal year.

AxoGen Profile

(Free Report)

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN – Free Report).

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.